$4.94
-2.0%Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells real-time water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it offers water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and AETHER brands for the food service, hospitality, convenience store, and health care markets. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
Chief Financial Officer
Compensation
$148,704
Controller
Director of Brand, Marketing & Business Development
President of Aether Water Systems
President, Chief Executive Officer & Director
Compensation
$395,500
Vice President of Quality, Regulatory, & Human Resources
During the last 12 months, insiders have purchased $59K worth of NEPH shares, with no selling activity reported.
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
13.2K
59.40K
0
0.00
+59K
+$59K
Nettis Lisa Marie
Director
$59K
No selling activity
Strong bullish signal with $59K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
1 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Unanimous insider buying: Zero selling combined with active buying is rare and typically very bullish. Insiders appear to see significant upside with limited downside risk.
NEPH - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 30, 2025 | April 30, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 12, 2024 | April 12, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 21, 2023 | April 21, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 13, 2022 | April 13, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 07, 2021 | April 07, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 08, 2020 | April 08, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 10, 2019 | April 10, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 11, 2018 | April 11, 2018 | 2018 | |
DEF 14A DEF 14A 2014 N/A | April 14, 2014 | May 16, 2014 | 2014 | |
DEF 14A DEF 14A 2013 N/A | April 11, 2013 | May 13, 2013 | 2013 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.